Chronic GVHD: progress in salvage treatment?
- PMID: 29170191
- DOI: 10.1182/blood-2017-10-808626
Chronic GVHD: progress in salvage treatment?
Conflict of interest statement
Conflict-of-interest disclosure: The author received honoraria for speakers’ bureau participation from Mallinckrodt, Novartis, and Amgen.
Comment on
-
Ibrutinib for chronic graft-versus-host disease after failure of prior therapy.Blood. 2017 Nov 23;130(21):2243-2250. doi: 10.1182/blood-2017-07-793786. Epub 2017 Sep 18. Blood. 2017. PMID: 28924018 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources